Immuno-Oncology | Specialty

Complex Scenarios in Advanced Melanoma: Examining Three Patient Cases

February 8th 2017

Despite significant developments on the advanced melanoma treatment front, “many clinical scenarios remain where there is no clear-cut course of action," said Robert H.I. Andtbacka, MD, CM, during a recent OncLive Peer Exchange®.

Nab-Paclitaxel Paired With Anti-PD-L1 Immunotherapies in TNBC Studies

February 8th 2017

Combination regimens that pair nab-paclitaxel with PD-L1 checkpoint blockade immunotherapy agents are emerging as a robust area of investigation in triple-negative breast cancer, bolstered by clinical trial results that establish the chemotherapeutic agent as an effective partner for other therapies.

Dr. Socinski on Recent Setbacks in Immunotherapy Combinations in NSCLC

February 7th 2017

Mark A. Socinski, MD, executive medical director of the Florida Hospital Cancer Institute, discusses recent setbacks in immunotherapy combinations in non–small cell lung cancer (NSCLC).

Atezolizumab/Bevacizumab Combo Attains 90% DCR in MSI-High mCRC

February 7th 2017

Patients with microsatellite-high metastatic colorectal cancer responded to an immunotherapy-containing regimen, according to results of a preliminary clinical evaluation presented at the 2017 Gastrointestinal Cancers Symposium.

Dr. Sklar on Challenges With Clinical Trials in Bladder Cancer

February 7th 2017

Geoffrey Sklar, MD, Chief Medical Officer, Chesapeake Urology Associates, discusses some of the challenges that come with conducting clinical trials in the treatment of patients with bladder cancer.

Dr. Figlin on the Plethora of Novel Agents in RCC

February 7th 2017

Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology and associate director of academic program development in the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, discusses the major novel agents at the forefront of the treatment landscape of renal cell carcinoma.

Jena French on Combinations With Immunotherapy in Thyroid Cancer

February 7th 2017

Jena D. French, PhD, instructor of Medicine, Division of Endocrinology, Metabolism and Diabetes, University of Colorado Denver, discusses combination regimens exploring immunotherapy and lenvatinib as treatment for patients with thyroid cancer.

Dr. Chiang on Immunotherapy in Patient Populations for Lung Cancer

February 7th 2017

Anne Chiang, MD, PhD, professor and thoracic oncologist at Yale Cancer Center, discusses immunotherapy in specific patient populations with lung cancer.

PD-1 Blockade Potential Comes to Light in Sarcoma Subtypes

February 6th 2017

An immunohistochemistry analysis of a large patient population demonstrated that several subtypes of difficult-to-treat sarcomas may respond to treatment with PD-1 pathway inhibiting immunotherapies, according to findings presented at the 2017 European Cancer Congress in Amsterdam.

Dr. Papadimitrakopoulou on Role of Immunotherapy in Lung Cancer

February 4th 2017

Vassiliki A. Papadimitrakopoulou, MD, professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the subset of patients with lung cancer which would derive the most benefit from immunotherapy.

FDA Grants Pembrolizumab Priority Review in Second-Line Bladder Cancer

February 4th 2017

The FDA has granted a priority review to a supplemental Biologics License Application for pembrolizumab for the treatment of patients with locally advanced or metastatic urothelial cancer who progress following platinum-containing chemotherapy, according to Merck, the manufacturer of the PD-1 inhibitor.

FDA Grants Priority Review to Frontline Pembrolizumab for Urothelial Carcinoma

February 4th 2017

The FDA has granted a priority review to pembrolizumab as a treatment for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma, according to Merck, the developer of the PD-1 inhibitor.

Dr. Weiss on Next Steps for Immunotherapy in Head and Neck Cancer

February 4th 2017

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses next steps for immunotherapy agents in the treatment of patients with head and neck cancer.

Dr. Lee on Immunotherapy's Future in RCC

February 3rd 2017

Chung-Han (Joe) Lee, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the future of immunotherapy in the treatment landscape of renal cell carcinoma.

Dr. Petrylak on FDA Approval of Nivolumab in Bladder Cancer

February 3rd 2017

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, discusses the FDA approval of nivolumab (Opdivo) as a treatment for patients with locally advanced unresectable or metastatic urothelial carcinoma following progression on a platinum-containing therapy, based on findings from the phase II CheckMate-275 study.

Dr. Motzer on Nivolumab/Ipilimumab Activity in RCC

February 3rd 2017

Robert J. Motzer, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, 2016 Giant of Cancer Care in Genitourinary Cancer, discusses the data seen thus far with nivolumab plus ipilimumab in the treatment of patients with renal cell carcinoma.

Dr. Socinski on Challenges Facing Immunotherapy Combinations

February 3rd 2017

Mark A. Socinski, MD, executive medical director of the Florida Hospital Cancer Institute, discusses challenges facing immunotherapy combinations in patients with non–small cell lung cancer (NSCLC).

FDA Approves Nivolumab for Urothelial Carcinoma

February 3rd 2017

The FDA has granted an accelerated approval to nivolumab (Opdivo) as a treatment for patients with locally advanced unresectable or metastatic urothelial carcinoma following progression on a platinum-containing therapy, based on findings from a phase II CheckMate-275 study.

Dr. Schoenfeld on Low-Dose Radiation Plus Immunotherapy in Head and Neck Cancer

February 2nd 2017

Jonathan D. Schoenfeld, MD, MPhil, MPH, director, melanoma radiation oncology, physician, assistant professor of radiation oncology, Harvard Medical School, Dana-Farber Cancer Institute, discusses potential combination regimens of low-dose radiation therapy and immunotherapy to treat patients with head and neck cancer.

Pembrolizumab Prolongs Survival in Second-Line Urothelial Carcinoma

February 2nd 2017

Treatment with the PD-1 inhibitor pembrolizumab significantly prolonged overall survival over investigators’ choice of chemotherapy in patients with recurrent advanced urothelial carcinoma, according to results reported at the 19th European Cancer Congress.